1. Comparison of injection‐site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study. (1st March 2018) Authors: Girolomoni, G.; Feldman, S.R.; Emery, P.; Ghil, J.; Keum, J.W.; Cheong, S.Y.; Hong, E. Journal: British journal of dermatology Issue: Volume 178:Number 3(2018) Page Start: e215 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Comparison of injection‐site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study. (30th January 2018) Authors: Girolomoni, G.; Feldman, S.R.; Emery, P.; Ghil, J.; Keum, J.W.; Cheong, S.Y.; Hong, E. Journal: British journal of dermatology Issue: Volume 178:Number 3(2018) Page Start: e215 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FRI0128 A Phase III Randomised, Double-Blind Clinical Study Comparing SB4, An Etanercept Biosimilar, With Etanercept Reference Product (Enbrel®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (24-Week Results). (9th June 2015) Authors: Vencovský, J.; Sylwestrzak, A.; Leszczyński, P.; Porawska, W.; Baranauskaite, A.; Tseluyko, V.; Zhdan, V.; Stasiuk, B.; Milasiene, R.; Barrera Rodriguez, A.A.; Cheong, S.Y.; Ghil, J.; Emery, P. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 467 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. FRI0161 Sustained Efficacy and Comparable Safety and Immunogenicity after Transition To SB5 (An Adalimumab Biosimilar) vs Continuation of The Adalimumab Reference Product in Patients with Rheumatoid Arthritis: Result of Phase III Study. (15th July 2016) Authors: Weinblatt, M.; Baranauskaite, A.; Niebrzydowski, J.; Dokoupilova, E.; Zielinska, A.; Sitek-Ziolkowska, K.; Jaworski, J.; Racewicz, A.; Pileckyte, M.; Jedrychowicz-Rosiak, K.; Zhdan, V.; Cheong, S.Y.; Ghil, J. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 487 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. THU0138 Secondary Efficacy Results Up To Week 24 from A Phase III Study Comparing SB5 (An Adalimumab Biosimiar) with Adalimumab Reference Product in Patients with Moderate To Severe Rheumatoid Arthritis despite Methotrexate Therapy. (15th July 2016) Authors: Kay, J.; Weinblatt, M.; Keystone, E.; Genovese, M.C.; Baranauskaite, A.; Cheong, S.Y.; Ghil, J. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 231 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. THU0146 Impact of anti-Drug Antibodies on Efficacy and Safety Up To Week 24 from A Phase III Study Comparing SB5 (An Adalimumab Biosimilar) with Adalimumab Reference Product in Patients with Moderate To Severe Rheumatoid Arthritis despite Methotrexate Therapy. (15th July 2016) Authors: Genovese, M.C.; Weinblatt, M.; Keystone, E.; Baranauskaite, A.; Cheong, S.Y.; Ghil, J. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 234 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. THU0150 Long-Term Safety and Efficacy of SB4 (Etanercept Biosimilar) in Patients with Rheumatoid Arthritis: Comparison between Continuing SB4 and Switching from Etanercept Reference Product To SB4. (15th July 2016) Authors: Emery, P.; Vencovský, J.; Sylwestrzak, A.; Leszczyński, P.; Porawska, W.; Stasiuk, B.; Hilt, J.; Mosterova, Z.; Cheong, S.Y.; Ghil, J. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 236 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. THU0184 Impact of immunogenicity on clinical efficacy and administration related reaction in tnf inhibitors: a pooled-analysis from three biosimilar studies in patients with rheumatoid arthritis. (12th June 2018) Authors: Emery, P.; Weinblatt, M.; Smolen, J.S.; Keystone, E.; Genovese, M.; Vencovsky, J.; Kay, J.; Hong, E.; Baek, Y.; Ghil, J. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 310 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. THU0201 A pooled analysis of three tnf-Α inhibitor biosimilar studies in patients with rheumatoid arthritis comparing radiographic progression by disease activity states. (12th June 2018) Authors: Smolen, J.S.; Weinblatt, M.; Emery, P.; Keystone, E.; Genovese, M.; Myung, G.; Hong, E.; Baek, I.; Lee, S.; Ghil, J. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 319 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗